Rheumazentrum Ruhrgebiet

Featured in: Favicon

nature.com Favicon

frontiersin.org Favicon

springer.com Favicon

biomedcentral.com Favicon

thelancet.com Favicon

jrheum.org Favicon

onlinelibrary.wiley.com Favicon

ard.bmj.com + 2 more

Articles

Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS

Oct 22, 2024 | academic.oup.com | Rheumazentrum Ruhrgebiet |Ruhr Bochum |Pieve Emanuele

Evaluate guselkumab efficacy, an anti-interleukin-23p19-subunit antibody, in patients with active psoriatic arthritis (PsA) and inadequate response to 1–2 tumour necrosis factor inhibitors (TNFi-IR), utilizing composite indices assessing disease activity across disease domains. In the Phase IIIb COSMOS trial, 285 adults with TNFi-IR PsA were randomized (2:1) to receive guselkumab 100 mg or placebo at Week (W)0, W4, then every 8 weeks through W44.
Correction: Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort | Arthritis Research & Therapy | Full Text

Oct 12, 2024 | arthritis-research.biomedcentral.com | Rheumazentrum Ruhrgebiet

Correction Open access Published: 11 October 2024 Arthritis Research & Therapy volume 26, Article number: 177 (2024) Cite this article The Original Article was published on 02 August 2023 Correction: Arthritis Res Ther 25, 136 (2023)Following publication of the original article [1], the authors reported an error under the Abstract, Result sub-section.
Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study

Oct 5, 2024 | acrjournals.onlinelibrary.wiley.com | Philip Mease |Xenofon Baraliakos |Rheumazentrum Ruhrgebiet |Vinod Chandran

INTRODUCTION Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease characterized by psoriasis of the skin and nails and joint disease affecting the peripheral and/or axial skeleton.1 Most patients with PsA present with multidomain disease requiring individualized treatment.2 Disease activity, previous therapies, prognostic factors (eg, pre-existing structural damage), comorbid conditions, and patient characteristics may influence response to therapy.3 Considering the...
Performance of standardized patient reported outcomes developed for spondyloarthritis in primary and concomitant forms of fibromyalgia - Arthritis Research & Therapy

Jul 27, 2024 | arthritis-research.biomedcentral.com | Rheumazentrum Ruhrgebiet |Ruhr Bochum

ReferencesSieper J, Poddubnyy D. Axial spondyloarthritis. Lancet (London England). 2017;390(10089):73–84. https://doi.org/10.1016/S0140-6736(16)31591-4. Article PubMed Google Scholar Zink A, Albrecht K. How frequent are musculoskeletal diseases in Germany? Z Rheumatol. 2016;75(4):346–53. https://doi.org/10.1007/s00393-016-0094-2. Article CAS PubMed Google Scholar Baraliakos X, Tsiami S, Redeker I, et al.
How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients

Jan 8, 2024 | academic.oup.com | Rheumazentrum Ruhrgebiet |Rheumatology Unit |Universidad de Oviedo

The ASSIST study investigated prescribing in routine psoriatic arthritis (PsA) care and whether the patient reported outcome: PsA Impact of Disease questionnaire (PsAID-12), impacted treatment. This study also assessed a range of patient and clinician factors and their relationship to PsAID-12 scoring and treatment modification. Patients with PsA were selected across the UK and Europe between July 2021-March 2022.
Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort | Arthritis Research & Therapy | Full Text

Aug 2, 2023 | arthritis-research.biomedcentral.com | Rheumazentrum Ruhrgebiet

PatientsRabbit-SpA is an observational, longitudinal cohort study, started by the German Rheumatism Research Centre in 2017. The main aim of the study is to examine long-term safety and effectiveness of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with a diagnosis of either axSpA or PsA. Participating rheumatology clinics or practices all over Germany enrol patients with at least one prior failure of a systemic therapy.
Correction: Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort | Arthritis Research & Therapy

Aug 2, 2023 | link.springer.com | Rheumazentrum Ruhrgebiet

Correction: Arthritis Res Ther 25, 136 (2023)Following publication of the original article [1], the authors reported an error under the Abstract, Result sub-section. The sentence currently reads:In both diagnoses, the proportion of patients with moderate depressive symptoms was 8% and 21% with severe symptoms. The sentence should read:In both diagnoses, 21% of patients exhibited moderate and 8% severe depressive symptoms. ReferencesReich A, Weiß A, Lindner L, et al.
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials - Advances in Therapy

Mar 30, 2023 | link.springer.com | Rheumazentrum Ruhrgebiet |Janssen Research

AbstractIntroductionEmerging evidence suggests psoriatic arthritis (PsA) with axial involvement (axPsA) and radiographic axial spondyloarthritis (r-axSpA) may possibly represent distinct disorders, with some differing clinical manifestations, genetic associations, and radiographic findings.
Confrontation with the spread of health-related misinformation on Social Networks: An Opinion Article

Feb 15, 2023 | frontiersin.org | Rheumazentrum Ruhrgebiet

Maria Polyzou1*, David Kiefer1, Xenofon Baraliakos1 and Philipp Sewerin1 1Rheumazentrum Ruhrgebiet, Germany The final, formatted version of the article will be published soon. Receive an email when it is updated Misinformation both in general and in the health sector is a serious social problem, which has taken on major proportions worldwide in the recent COVID-19 pandemic.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →